Incorporating patient preferences into drug development and regulatory decision making: Results from a quantitative pilot study with cancer patients, carers, and regulators-Reference-Cited by-同舟云学术

Incorporating patient preferences into drug development and regulatory decision making: Results from a quantitative pilot study with cancer patients, carers, and regulators

Published:2016-02-17 Issue:5 Volume:99 Page:548-554
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Postmus D¹²,Mavris M¹,Hillege HL²,Salmonson T¹³,Ryll B⁴,Plate A⁵,Moulon I¹,Eichler H-G¹,Bere N¹,Pignatti F¹

Affiliation:

1. European Medicines Agency; London UK

2. University of Groningen; University Medical Center Groningen; The Netherlands

3. Läkemedelsverket Medical Products Agency; Uppsala Sweden

4. Melanoma Patient Network Europe

5. Myeloma Patients Europe

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpt.332/fullpdf

Reference13 articles.

1. Medical Device Innovation Consortium A framework for incorporating information on patient preferences regarding benefit and risk into regulatory assessments of new medical technology 2015 http://mdic.org/wp-content/uploads/2015/05/MDIC_PCBR_Framework_Proof5_Web.pdf

2. Goal-based construction of preferences: Task goals and the prominence effect;Fischer;Manag. Sci.,1999

3. Rational choice and the framing of decisions;Tversky;J. Bus.,1986

4. Context-dependent preferences;Tversky;Manag. Sci.,1993

5. Hunter , N.L. Califf , R.M. FDA announces first-ever Patient Engagement Advisory Committee 2015 http://blogs.fda.gov/fdavoice/index.php/2015/09/fda-announces-first-ever-patient-engagement-advisory-committee/

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can the General Public Be a Proxy for an “At-Risk” Group in a Patient Preference Study? A Disease Prevention Example in Rheumatoid Arthritis;Medical Decision Making;2024-01-19

2. Two Methods, One Story? Comparing Results of a Choice Experiment and Multidimensional Thresholding From a Clinician Preference Study in Aneurysmal Subarachnoid Hemorrhage;Value in Health;2024-01

3. Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer setting;European Journal of Cancer;2024-01

4. Adalimumab versus Infliximab Treatment Outcome in Ulcerative Colitis: Application of EQ-5D, Visual Analogue Scale, and IBDQ-9 Measures: A Prospective Observational Study;Current Drug Safety;2023-11

5. How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action;Frontiers in Pharmacology;2023-08-16